海力風電(301155.SZ):“海上風電場大兆瓦配套設備製造基地項目”結項、結餘募集資金及超募資金擬用於“風電高端裝備製造項目(一期)”
格隆匯1月2日丨海力風電(301155.SZ)公佈,公司於2022年12月30日召開了第二屆董事會第十三次會議、第二屆監事會第十二次會議,審議通過了《關於首次公開發行股票募投項目結項並使用結餘募集資金及超募資金投入新項目的議案》,同意公司將首發募投項目“海上風電場大兆瓦配套設備製造基地項目”結項,並擬使用結餘募集資金及超募資金投建“風電高端裝備製造項目(一期)”,項目建設主體為公司全資子公司江蘇海力風能設備有限公司。上述事項尚需提交股東大會審議,董事會同時提請股東大會一併授權公司經營管理層全權辦理上述事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.